Fulvestrant

Fulvestrant.svg
Fulvestrant, sold under the brand name Faslodex among others, is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.[2] It is given by injection into a muscle.[3]

Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved.[4] It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.[4]

Fulvestrant was approved for medical use in the United States in 2002.[5]

Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer or locally advanced unresectable disease in postmenopausal women; it is given by injection.[3] A 2017 Cochrane review found it is as safe and effective as first line or second line endocrine therapy.[3]

It is also used to treat HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after first-line endocrine therapy.[2]

It should not be used in women with kidney failure or who are pregnant.[2][6]

Due to the medication having a similar chemical structure to estrogen, it can interact with immunoassays for blood estradiol concentrations and show falsely elevated results.[7] This can improperly lead to discontinuing the treatment.[7]

Very common (occurring in more than 10% of people) adverse effects include nausea, injection site reactions, weakness, and elevated transaminases. Common (between 1% and 10%) adverse effects include urinary tract infections, hypersensitivity reactions, loss of appetite, headache, blood clots in veins, hot flushes, vomiting, diarrhea, elevated bilirubin, rashes, and back pain.[6]

This page was last edited on 20 May 2018, at 03:15 (UTC).
Reference: https://en.wikipedia.org/wiki/ICI-182,780 under CC BY-SA license.

Related Topics

Recently Viewed